LymphoSign Test-Kit : A fine classification of non-Hodgkin's lymphomas
The LymphoSign Kit, plays a crucial role in establishing accurate diagnoses and treatment plans for non-Hodgkin’s lymphoma. Leveraging RNA expression levels from over 130 relevant gene markers, this state-of-the-art method provides valuable insights into disease progression. Its simple, fast protocol and suitability for challenging samples make it a powerful tool in non-Hodgkin’s lymphoma research and patient care .
LymphoSign Kit
Helps to establish an accurate diagnosis and treatment plan for non-Hodgkin's lymphoma
Non-Hodgkin's lymphoma is a type of cancer that originates in the lymphatic system, which is part of the immune system. It is characterized by the abnormal growth of lymphocytes, a type of white blood cell, and can occur in any part of the body.
There are more than 80 types of non-Hodgkin's lymphoma, some of which are rare and difficult to characterize, Hence, Accurate knowledge has become a key issue.
Many advances have been made since the introduction of the WHO classification in 2001. But the risk of errors remains higher than in other pathologies.
The LymphoSign test developed by Genexpath offers a detailed classification of these lymphomas.
Genexpath's LymphoSign test is a state-of-the-art method for evaluating the stage of differentiation in non-Hodgkin's lymphoma (NHL) tumor cells. By leveraging RNA expression levels of over 130 relevant gene markers, this solution provides valuable insights into the disease progression.
Use of the test
The GENEXPATH LymphoSign test utilizes a ligation-dependent RT-PCR (LD-RT-PCR) method, enabling the simultaneous assessment of expression levels for a wide range of genetic markers. This semi-quantitative technique employs specific pairs of oligonucleotide probes to target genes, somatic mutations, and chromosomal translocations, providing comprehensive molecular information.
A simple and fast protocol
- No purification required until library preparation, minimizing material loss and maintaining high sensitivity.
- Short genetic sequences targeted (40-60 bases), ensuring robustness against RNA degradation.
- Particularly suitable for analyzing difficult biological samples like paraffin-fixed tissue biopsies.
- 105 sequences per sample sufficient for analyzable expression profiles, allowing high-throughput analysis.
- Libraries can be loaded simultaneously with other sequencing libraries, optimizing cost efficiency.
Precise computer analysis based on dedicated software
Once sequencing has been completed, the FASTQ file can be uploaded to the RT-MIS platform. which, after just a few minutes of analysis a report with the expression signature of the various genes and an AI-predicted classification according to the 2017 WHO classification, offering users a complete solution.
| Handling duration | ≃4h |
| Actual working time | ≃1h-1h30 |
| Type of Nucleic acid | RNA |
| Input quantity | Between 50 and 500ng of RNA in a volume of 2μl |
| Type of cancer | Non-hodgkin lymphoma |
| Contents of the reagent kit | Probes targeting 137 markers, barcodes, sequence primers |
| Method | Ligation dependent RT-PCR |
| Description | Compare the expression profiles obtained from genes, somatic mutations or chromosomal translocations with those of the main types of non-Hodgkin's lymphoma. |
| Equipment compatibility | MiSeq, NextSeq 500, NextSeq 550 Illumina® |
| Type of samples | Tissue biopsies at room temperature, frozen or fixed and included in paraffin |
| Technology | Next Generation Sequencing |
Thanks to the LymphoSign Test-Kit, the classification of lymphoma has become a simple process.
Now, you can Purchase the Kit that matches your needs and be sure to obtain the best results in a short time
|
Description |
Cat# |
Cond. |
|
LymphoSign Test-Kit |
8 reactions |
|
|
16 reactions |
||
|
24 reactions |
||
|
48 reactions |
For more information:
Consult the reference publication LymphoSign Test-Kit
|
⚠ |
These products are medical devices. Please follow the manufacturer's instructions |
 |